Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin

Ying, Shui‐Wang; Niles, Lennard P.; Crocker, Candice E.

doi:10.1016/0922-4106(93)90084-m

Cited by 97 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Today, many of the oncostatic properties of melatonin have been fairly well described (Vijayalaxmi et al, 2002), and evidence from experimental studies strongly suggests a link between melatonin and tumour suppression (Schernhammer and Hankinson, 2003). In vitro studies, although not entirely consistent (Panzer et al, 1998), give support to a reduction in the growth of malignant cells of the breast (Hill and Blask, 1988;Cos et al, 1996Cos et al, , 1998Cos et al, , 2002Mediavilla et al, 1999) and other tumour sites (Sze et al, 1993;Ying et al, 1993;Petranka et al, 1999;Shiu et al, 1999;Kanishi et al, 2000) by both pharmacological and physiologic doses of melatonin. In rodent models, pinealectomy boosts tumour growth (Tamarkin et al, 1981), whereas exogenous melatonin administration exerts anti-initiating (Musatov et al, 1999) and oncostatic activity (Anisimov et al, 1997Cini et al, 1998;Mocchegiani et al, 1999) in various chemically induced cancers.…”

Section: Cancer-protective Effects Of Melatoninmentioning

confidence: 99%

“…In fact, to date, melatonin has been shown to be oncostatic for a variety of tumour cells in experimental carcinogenesis (Sze et al, 1993;Ying et al, 1993;Petranka et al, 1999;Shiu et al, 1999;Kanishi et al, 2000). Reports show that melatonin exhibits a growth-inhibitory effect on endometrial (Kanishi et al, 2000) and ovarian carcinoma cell lines (Petranka et al, 1999), Lewis lung carcinoma (Mocchegiani et al, 1999), prostate tumour cells (Laufer et al, 1999), and intestinal tumours (Anisimov et al, 1997(Anisimov et al, , 2000a, for example.…”

Section: Cancer-protective Effects Of Melatoninmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

2004

View full text Add to dashboard Cite

The suprachiasmatic nuclei in the hypothalamus, one of the most important physiological determinants of alertness and performance, drive a circadian pacemaker in mammals, with an intrinsic period averaging 24 h. Light is the primary stimulus to the disruption and resetting of this pacemaker, which is expressed in changing melatonin rhythms. Melatonin production in humans decreases when people are exposed to light at night. Since melatonin shows potential oncostatic action in a variety of tumours, it is possible that lowered serum melatonin levels caused by exposure to light at night enhance the general tumour development. Cancer is the second leading cause of death in industrialised countries like the United States, where a significant proportion of workers engage in shift work, making a hypothesised relation between light exposure at night and cancer risk relevant. Observational studies support an association between night work and cancer risk. We hypothesise that the potential primary culprit for this observed association is the lack of melatonin, a cancer-protective agent whose production is severely diminished in people exposed to light at night.

show abstract

Section: Cancer-protective Effects Of Melatoninmentioning

confidence: 99%

Section: Cancer-protective Effects Of Melatoninmentioning

confidence: 99%

Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

2004

View full text Add to dashboard Cite

show abstract

“…34 A desynchronized production of melatonin by the pineal gland was found in flight attendants, because of disruption of the circadian rhythm. 5 Melatonin was found to have oncosuppressive properties on melanoma cells 35,36 and an oncostatic effect on mammary glands both in vivo and in vitro. 37,38 Melatonin could also act as a naturally occurring antiestrogen, thereby influencing the proliferative rate of mammary tumor cells.…”

Section: Buja Et Al 102mentioning

confidence: 99%

Cancer Incidence among Female Flight Attendants: A Meta-Analysis of Published Data

Buja

Mastrangelo

Perissinotto

et al. 2006

Journal of Women's Health

View full text Add to dashboard Cite

Background: Flight attendants are exposed to cosmic ionizing radiation and other potential cancer risk factors, but only recently have epidemiological studies been performed to assess the risk of cancer among these workers. The aim of the present work was to evaluate the incidence of various types of cancer among female cabin attendants by combining cancer incidence estimates reported in published studies.Methods: All follow-up studies reporting standardized incidence ratio (SIR) for cancer among female flight attendants were obtained from online databases and analyzed. A metaanalysis was performed by applying Bayesian hierarchical models, which take into account studies that reported SIR ‫؍‬ 0 and natural heterogeneity of study-specific SIRs.Results: A total of seven published studies reporting SIR for several cancer types were extracted. Meta-analysis showed a significant excess of melanoma (meta-SIR 2.15, 95% posterior interval [PI] 1.56-2.88) and breast carcinoma (meta-SIR 1.40; PI 1.19-1.65) and a slight but not significant excess of cancer incidence across types (meta-SIR 1.11, PI 0.98-1.25).Conclusions: Although further studies are necessary to clarify the exact role of occupational exposure, all airlines should, as some companies do, estimate radiation dose, organize the schedules of crew members in order to reduce further exposure in highly exposed flight attendants, inform crew members about health risks, and give special protection to pregnant women.

show abstract

“…30). Several in vitro studies have reported a reduction in the growth of malignant cells and/or tumors of the breast (31)(32)(33)(34)(35) prostate (36)(37)(38)(39)(40)(41), and other tumor sites (42)(43)(44)(45)(46) by both pharmacologic and physiologic doses of melatonin. In rodent models, pinealectomy has been found to enhance tumor growth (47), and exogenous melatonin administration has shown anti-initiating (48) and oncostatic (49)(50)(51)(52) activities in various chemically induced cancers as well as in virus-transmitted tumors in mice (53).…”

Section: Cancer Epidemiol Biomarkers Prev 2008;17(12) December 2008mentioning

confidence: 99%

Melatonin as a Biomarker of Circadian Dysregulation

Mirick

Davis

2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

144

108

View full text Add to dashboard Cite

It would be most useful to identify a biomarker of circadian dysregulation that could be used in epidemiologic studies of the effects of circadian disruption in humans. An indicator of circulating melatonin level has been shown to be a good biomarker of circadian dysregulation and has been associated with nightshift work and exposure to light-at-night in both laboratorybased and field studies. Among other circadian markers (such as core body temperature), it remains comparatively robust in the presence of various external influences. It can be reliably measured directly and indirectly through its metabolites in urine, blood, and saliva. Urinary melatonin has been shown to be stable over time, making it useful in epidemiologic studies in which laboratory processing is not immediately available, as well as studies of cancer with long latency periods. Several studies have shown melatonin to be useful in measuring diurnal type, which is of increasing interest as it becomes more apparent that successful adaptation to shift work may be dependent on diurnal preference. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3306 -13)

show abstract

Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin

Cited by 97 publications

References 28 publications

Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

Cancer Incidence among Female Flight Attendants: A Meta-Analysis of Published Data

Melatonin as a Biomarker of Circadian Dysregulation

Contact Info

Product

Resources

About